77
Registered trials
41
Recruiting
26
Completed trials
40
Sponsors
25
Countries
Phase III:
17
Phase II/III:
3
Phase II:
24
Phase I/II:
14
Phase IV:
3
Phase I:
1
Phase I (Other):
3
Phase I (FiH):
12
Oversight events:
3 serious breaches
36 temporary halts
1 urgent safety measure
3 unexpected events
5 corrective measures
across 13 trials
View oversight register →
Indications tested
Systemic lupus erythematosus
4
Lupus nephritis
3
Myelodysplastic syndrome
3
Acute myeloid leukaemia
2
Diffuse large B-cell lymphoma recurrent
2
Follicle centre lymphoma follicular grade I II III
1
Immune-mediated myositis
1
Mantle cell lymphoma refractory
1
Non-small cell lung cancer
1
Rheumatoid arthritis
1
Squamous cell carcinoma of head and neck
1
T-cell lymphoma
1
Sponsors using this IMP
Novartis Pharma AG
12
Ospedale Pediatrico Bambino Gesu
6
Iovance Biotherapeutics Inc.
5
Celgene Corp.
4
Prinses Maxima Centrum voor Kinderoncologie B.V.
4
Autolus Limited
3
Allogene Therapeutics Inc.
2
Cabaletta Bio Inc.
2
Cellectis
2
Fondazione Gimema Franco Mandelli Onlus
2
Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
2
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
2
All trials
77 totalShowing 1–24 of 77 trials